RheoTek Medical

What RheoTek Medical does

RheoTek Medical Inc is a Philadelphia-based, privately held medical device company founded in 2023 that is developing a needle-free precision drug delivery platform for aesthetic and medical dermatology applications. The platform technology is engineered to deliver injections with highly controlled depth targeting across the epidermis, dermis, fat, and muscle layers, while providing variable volume delivery, predictable dispersion, reduced patient pain, and zero product waste. The device holds US Patent Pending status and is currently under clinical evaluation; it has not received FDA approval and is not commercially available.

The company positions the platform across multiple application verticals: hair rejuvenation, facial aesthetics, skin cancer treatment, general medical dermatology, scar revision, hyperhidrosis, and as a delivery vehicle for novel therapeutics. Because the product is pre-revenue, RheoTek has no active distribution channels or paying customers. Its go-to-market activity is limited to a corporate website, an email newsletter, and selective industry-conference engagement, including a speaker slot at the April 2023 Aesthetics Innovation Summit. The firm has 1–10 employees, has not disclosed any institutional funding rounds, partnerships, or M&A activity in the source material, and is operated as a founder-controlled entity.

RheoTek is led by co-founders Daniel Mazzaferro, MD, MBA (President and Board Member; practicing Plastic and Reconstructive Surgeon) and Scott Bartlett, MD (VP and Board Member; Professor of Surgery at the University of Pennsylvania, with prior commercialization of a medical device, InfantEar). The leadership section also lists Steve Schultz as Chief Executive Officer, indicating an early executive layer beyond the two physician-founders, though the operating headcount remains in the 1–10 range.

Name

RheoTek Medical

Legal name

RheoTek Medical Inc

Website

https://rheotekmedical.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

RheoTek Medical Inc is a Philadelphia-based, pre-revenue medical device company developing a US patent-pending precision drug delivery platform for targeted injections in aesthetics, medical dermatology, and skin cancer applications.

Ownership category

akta.pro rank

Product category

Drug Delivery Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Drug delivery platform
• Precision injection technology
• Medical dermatology devices
• Aesthetic injection systems
• Injectable therapeutics delivery

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-Revenue Stage: RheoTek Medical is a pre-revenue medical device company. The platform technology is under clinical evaluation and is not currently for sale. The company has not yet received FDA approval for its drug delivery technology.

Go-to-market motion1 record

Marketing channels3 records

Core offering

RheoTek Medical develops a drug delivery technology platform that enables highly precise injection delivery to specific tissue depths (epidermis, dermis, fat, or muscle) with optimal dispersion and reduced patient pain. The platform supports variable volume delivery and reproducible clinical outcomes for applications in face and hair aesthetics, medical dermatology, skin cancer treatment, scars, hyperhidrosis, and novel therapeutics. The product is under clinical evaluation and is not yet FDA approved or commercially available.

Product overview

RheoTek Medical offers a single unified drug delivery technology platform focused on precision injection systems. The platform enables highly precise injections at configurable tissue depths (epidermis, dermis, fat, or muscle) with features including variable volume delivery, predictable dispersion, reduced pain, and minimal product waste. The technology is under clinical evaluation and is not yet FDA approved or commercially available. Key application areas include hair rejuvenation, face rejuvenation, skin cancer treatment, medical dermatology, scar treatment, and excess sweating.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Delivery Technology Platform

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Galderma: Global dermatology-focused pharmaceutical and aesthetics company offering injectables (Restylane, Sculptra, Dysport) and skincare. Comparable as a broad incumbent across RheoTek's primary aesthetic and medical dermatology use cases.
• Cutera: Aesthetic medical device company offering laser- and energy-based systems for skin rejuvenation, hair removal, and dermatology. Comparable as an aesthetics-device incumbent targeting the same dermatology and facial rejuvenation practices.
• Crown Laboratories: Dermatology-focused company offering prescription and aesthetics products (skin care, micro-needling devices, intradermal treatments). Comparable as a multi-product dermatology/aesthetics platform.
• Evolus: Aesthetics company marketing Jeuveau (prabotulinumtoxinA) injectable neuromodulator. Comparable as a pure-play aesthetics injectable provider serving the same physician channel RheoTek targets with its face rejuvenation use case.
• Apyx Medical: Medical device company offering energy-based (plasma/RF) technologies for aesthetics and surgical applications. Comparable as a device-platform company selling into plastic surgeons and dermatologists — the same clinical channel RheoTek plans to serve.

Direct peers

• Sientra: Aesthetics medical device company focused on breast implants, bioCorneum scar treatment, and dermal matrices. Comparable as an aesthetics-focused medical device platform serving plastic surgeons and dermatologists — the same customer base RheoTek targets.
• Revance Therapeutics: Aesthetics-focused biopharmaceutical company developing injectable neuromodulators and proprietary delivery platforms (e.g., RHA dermal fillers, DaxibotulinumtoxinA). Directly comparable as a precision-injection-focused aesthetics platform with both device and therapeutic components.
• Sensus Healthcare: Medical device company specializing in superficial radiation therapy (SRT) for skin cancer and keloid treatment. Comparable because RheoTek explicitly lists skin cancer as a primary use case and Sensus serves the same dermatology clinical channel.

Others

• West Pharmaceutical Services: Global manufacturer of drug delivery components including injectable device systems, prefilled syringe components, and elastomeric seals. Comparable as an enabling supplier in the injection drug delivery ecosystem that RheoTek could partner with or compete against for device platforms.

Emerging players

• Aerolase: Medical and aesthetic laser device company offering portable dermatology/aesthetics laser systems (e.g., LightPod Neo). Comparable as a smaller, dermatology-focused device player serving the same clinical practice channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RheoTek Medical